About the Company
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NTRA News
Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc
Natera Inc (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, has seen a recent insider transaction ...
CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), has sold 2,552 shares of the company on April 23, 2024, ...
Understanding the 3.73% Volatility Levels of Natera Inc’s (NTRA) Stock in the Past 30 Days
Volatility was left at 3.73%, however, over the last 30 days, the volatility rate increased by 4.21%, as shares surge +0.91% for the moving average over the last 20 days. Over the last 50 days, in ...
Natera (NTRA) Price Target Increased by 7.38% to 102.96
The average one-year price target for Natera (NasdaqGS:NTRA) has been revised to 102.96 / share. This is an increase of 7.38% ...
Preimplantation Genetic Testing Market to Grow at 8.1% CAGR, Reaching USD 1648.6 Million by 2033
According to a recent report by Market.us, the Global Preimplantation Genetic Testing Market size is expected to be worth around USD 1,648.6 Million by 2033 from USD 756.6 Million in 2023, growing at ...
Reason for the Surge of ICON Public Limited Company (ICLR)
“Solid stock selection in life sciences tools & services was mainly due to double-digit gains from clinical genetic testing ...
Artisan Global Equity Fund Q1 2024 Commentary
Artisan Global Equity Fund's portfolio solidly outperformed the MSCI AC World Index. Click here to read the full fund letter.
AGW-Mental Wellbeing 2024 - Mid-size companies
America's Greatest Workplaces for Mental Wellbeing 2024. Mental well-being is an increasingly important concern for U.S. workers—which means it's increasingly important for U.S.
Thermo Fisher Outperforms in Q1 with Strong Revenue and Earnings Growth, Justifying Buy Rating
Analyst Puneet Souda from Leerink Partners assigned a Buy rating on Thermo Fisher (TMO – Research Report) and keeping the price target at ...
9 Best Biotech ETFs for 2024
Biotechnology uses living organisms to develop new medicines and technologies that benefit both environmental and social ...
Preimplantation Genetic Diagnosis Market Latest Trends, Share, Size, Regional Analysis, Prominent Players and Forecast to 2024 to 2032
Preimplantation genetic testing helps people to avoid the hereditary disorders that prevail in the family to be carried into ...
Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)
Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), has sold 1,523 shares of the company on April 23, ...
Loading the latest forecasts...